WO2005108353A3 - Compounds for treating neurologic diseases, otologic diseases, or ophthalmologic diseases and methods of use thereof - Google Patents
Compounds for treating neurologic diseases, otologic diseases, or ophthalmologic diseases and methods of use thereof Download PDFInfo
- Publication number
- WO2005108353A3 WO2005108353A3 PCT/US2005/016132 US2005016132W WO2005108353A3 WO 2005108353 A3 WO2005108353 A3 WO 2005108353A3 US 2005016132 W US2005016132 W US 2005016132W WO 2005108353 A3 WO2005108353 A3 WO 2005108353A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- compounds
- methods
- otologic
- ophthalmologic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/17—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing carboxyl groups bound to the carbon skeleton
- C07C309/18—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing carboxyl groups bound to the carbon skeleton containing amino groups bound to the same carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Described herein are compounds and methods for treating or preventing a neurologic, otologic, or ophthalmologic disease in a subject.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56872004P | 2004-05-06 | 2004-05-06 | |
| US60/568,720 | 2004-05-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005108353A2 WO2005108353A2 (en) | 2005-11-17 |
| WO2005108353A3 true WO2005108353A3 (en) | 2006-10-26 |
Family
ID=35320784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/016132 WO2005108353A2 (en) | 2004-05-06 | 2005-05-06 | Compounds for treating neurologic diseases, otologic diseases, or ophthalmologic diseases and methods of use thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2005108353A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006037133A1 (en) * | 2004-09-29 | 2006-04-06 | Ceptor Corporation | Treatment of traumatic or degenerative neurologic, otologic, or ophthalmologic diseases with targeted protease inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559038A (en) * | 1994-05-04 | 1996-09-24 | The Regents Of The University Of Colorado | Gas chromatography/mass spectrometry determination of oxidized sulfhydryl amino acids |
| US20020025926A1 (en) * | 2000-08-30 | 2002-02-28 | Hebert Rolland F. | Enantiomers of S-adenosyl-l-methionine |
| WO2003080049A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
-
2005
- 2005-05-06 WO PCT/US2005/016132 patent/WO2005108353A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559038A (en) * | 1994-05-04 | 1996-09-24 | The Regents Of The University Of Colorado | Gas chromatography/mass spectrometry determination of oxidized sulfhydryl amino acids |
| US20020025926A1 (en) * | 2000-08-30 | 2002-02-28 | Hebert Rolland F. | Enantiomers of S-adenosyl-l-methionine |
| WO2003080049A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005108353A2 (en) | 2005-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005067546A3 (en) | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | |
| WO2007112052A3 (en) | Formulations and methods for vascular permeability-related diseases or conditions | |
| WO2004113275A3 (en) | Methods and compositions for treating amyloid-related diseases | |
| PL380828A1 (en) | Phosphoranians, amidomonophosphoranians, amidobisphosphoranians for treating virus diseases | |
| AP2378A (en) | Sulfonamide derivatives for the treatment of diseases. | |
| AP2359A (en) | Sulfonamide derivatives for the treatment of diseases. | |
| IL177284A0 (en) | Management of ophthalmologic disorders, including macular degeneration | |
| PL1761266T3 (en) | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | |
| EP1742641A4 (en) | Methods and compositions for detecting and treating retinal diseases | |
| WO2006078287A3 (en) | Pde4b inhibitors and uses therefor | |
| WO2005097119A3 (en) | Pten inhibitors | |
| WO2006127900A3 (en) | Tl1a in the treatment of disease | |
| WO2006002437A3 (en) | Treatment of conditions involving demyelination | |
| WO2005052002A3 (en) | Single-domain antibodies and uses thereof | |
| WO2007051785A3 (en) | Use of sdf-1 for the treatment and/or prevention of neurological diseases | |
| BRPI0612005A2 (en) | prophylactic or therapeutic agent, ophthalmic composition, selenoprotein p use, and method for preventing / treating a corneal / conjunctival disease | |
| WO2007048097A3 (en) | Anbrosteeone derivatives and method of use thereof | |
| EP1545555A4 (en) | Compositions and methods for treating epithelial and retinal tissue diseases | |
| WO2004091436A3 (en) | Methods and compositions for treating ocular disease | |
| AU2002222180A1 (en) | The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity | |
| EP1768656A4 (en) | Treatment for ocular disease | |
| EP1631306A4 (en) | Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof | |
| WO2005124563A3 (en) | Compounds and kits for treating muscle disorders and methods of use thereof | |
| WO2004100873A3 (en) | Compounds, compositions, and methods | |
| WO2006127966A3 (en) | Compositions and methods for enhancing axon regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |